{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:30:04Z","timestamp":1792416604775,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bbcan.2022.188823","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:13:16Z","timestamp":1665555196000},"page":"188823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management"],"prefix":"10.1016","volume":"1877","author":[{"given":"Mimma","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Pezzicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2022.188823_bb0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-014-1702-7","article-title":"Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma","volume":"466","author":"Hayes","year":"2015","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbcan.2022.188823_bb0015","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge","volume":"11","author":"Cali\u00f2","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2022.188823_bb0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"7456","key":"10.1016\/j.bbcan.2022.188823_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188823_bb0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/PAS.0b013e31824dd972","article-title":"TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients","volume":"36","author":"Sukov","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0035","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41379-018-0051-5","article-title":"RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations","volume":"31","author":"Wang","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0040","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/PAS.0000000000000720","article-title":"TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity","volume":"40","author":"Argani","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0045","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41379-020-00713-6","article-title":"TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1","volume":"34","author":"Cali\u00f2","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/modpathol.2017.99","article-title":"Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays","volume":"31","author":"Skala","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0055","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/modpathol.2017.24","article-title":"TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management","volume":"30","author":"Gupta","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0060","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41379-018-0128-1","article-title":"VEGFA amplification\/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations","volume":"32","author":"Cali\u00f2","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(93)90050-V","article-title":"Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype","volume":"65","author":"Meloni","year":"1993","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbcan.2022.188823_bb0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/hmg\/5.9.1333","article-title":"The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene","volume":"5","author":"Sidhar","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbcan.2022.188823_bb0075","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/sj.onc.1201394","article-title":"Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma","volume":"1","author":"Clark","year":"1997","journal-title":"Oncogen"},{"issue":"1","key":"10.1016\/j.bbcan.2022.188823_bb0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9440(10)61684-7","article-title":"Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents","volume":"59","author":"Argani","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0085","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/sj.onc.1206686","article-title":"A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)","volume":"22","author":"Argani","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2022.188823_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.onc.1204074","article-title":"The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25","volume":"20","author":"Ladanyi","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2022.188823_bb0095","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","article-title":"Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2022.188823_bb0100","first-page":"784993","article-title":"Xp11.2 translocation renal cell carcinoma with TFE3 rearrangement: distinct morphological features and prognosis with different fusion partners. Front","volume":"11","author":"Ge","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.bbcan.2022.188823_bb0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pathol.2019.11.006","article-title":"Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets","volume":"52","author":"Cali\u00f2","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.bbcan.2022.188823_bb0110","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"3","author":"Bakouny","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2022.188823_bb0115","first-page":"22","article-title":"MALAT1 long non-coding RNA: functional implications","volume":"6","author":"Arun","year":"2020","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.bbcan.2022.188823_bb0120","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41379-021-00858-y","article-title":"Diagnostic utility of one-stop fusion gene panel to detect TFE3\/TFEB gene rearrangement and amplification in renal cell carcinomas","volume":"34","author":"Harada","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.bbcan.2022.188823_bb0130","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/hmg\/ddg178","article-title":"Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution","volume":"12","author":"Kuiper","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbcan.2022.188823_bb0135","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1101\/gad.12.19.3084","article-title":"Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene","volume":"12","author":"Hua","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2022.188823_bb0140","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1073\/pnas.96.23.13130","article-title":"Specificity in transforming growth factor beta-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor muE3, and Smad proteins","volume":"96","author":"Hua","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2022.188823_bb0145","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/MCB.19.4.2946","article-title":"Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins","volume":"19","author":"Tian","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0150","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","article-title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers","volume":"34","author":"Argani","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/emboj.2011.257","article-title":"Regulation of TFEB and V-ATPases by mTORC1","volume":"30","author":"Pe\u00f1a-Llopis","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2022.188823_bb0160","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ajpath.2021.07.007","article-title":"mTOR inhibition increases transcription factor E3 (TFE3) activity and modulates programmed death-ligand 1 (PD-L1) expression in translocation renal cell carcinoma","volume":"191","author":"Lee","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-019-1101-7","article-title":"TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas","volume":"39","author":"Yin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188823_bb0170","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41379-018-0051-5","article-title":"RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations","volume":"31","author":"Wang","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0175","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-022-03380-x","article-title":"TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms","author":"Cali\u00f2","year":"2022","journal-title":"Virchows Arch."},{"issue":"7","key":"10.1016\/j.bbcan.2022.188823_bb0180","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","article-title":"MITF in melanoma: mechanisms behind its expression and activity","volume":"72","author":"Hartman","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188823_bb0185","doi-asserted-by":"crossref","first-page":"12382","DOI":"10.1002\/jcb.28504","article-title":"AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors","volume":"120","author":"Pang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbcan.2022.188823_bb0190","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/PAS.0b013e31828a69ae","article-title":"Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service","volume":"37","author":"Green","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-011-1127-5","article-title":"Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma","volume":"459","author":"Kim","year":"2011","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbcan.2022.188823_bb0200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/PAS.0b013e31827e17cb","article-title":"TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum","volume":"37","author":"Rao","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1066896914562280","article-title":"Xp11 translocation renal cell carcinoma morphologically mimicking clear cell-papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas","volume":"23","author":"Parihar","year":"2015","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0210","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.humpath.2011.07.001","article-title":"A distinctive translocation carcinoma of the kidney; \u201crosette forming,\u201d t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases","volume":"43","author":"Petersson","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT family translocation renal cell carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0220","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/modpathol.2009.58","article-title":"Cathepsin-K immunoreactivity distinguishes MiTF\/TFE family renal translocation carcinomas from other renal carcinomas","volume":"22","author":"Martignoni","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000146007.54092.37","article-title":"Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR","volume":"29","author":"Argani","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0230","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/modpathol.2017.144","article-title":"T(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa\/epithelioid angiomyolipoma","volume":"31","author":"Cali\u00f2","year":"2018","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188823_bb0235","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","article-title":"TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease","volume":"17","author":"Baba","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188823_bb0240","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41379-021-00803-z","article-title":"TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma","volume":"34","author":"Wang","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0245","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/cancers13102441","article-title":"Cathepsin K: a novel diagnostic and predictive biomarker for renal tumors","volume":"13","author":"Cali\u00f2","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2022.188823_bb0250","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/modpathol.2013.208","article-title":"Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage","volume":"27","author":"Ellis","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0255","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/modpathol.2011.93","article-title":"Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions","volume":"24","author":"Martignoni","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0260","doi-asserted-by":"crossref","first-page":"610360","DOI":"10.3389\/pore.2021.610360","article-title":"Factors associated with survival from Xp11.2 translocation renal cell carcinoma diagnosis-a systematic review and pooled analysis","volume":"27","author":"Wu","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.bbcan.2022.188823_bb0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.anndiagpath.2014.10.002","article-title":"Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature","volume":"18","author":"Peckova","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0270","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2022.188823_bb0275","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-20-3084","article-title":"Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to Nivolumab in metastatic clear cell renal cell carcinoma","volume":"27","author":"Ficial","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188823_bb0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-018-0482-z","article-title":"Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders","volume":"6","author":"Boil\u00e8ve","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"suppl","key":"10.1016\/j.bbcan.2022.188823_bb0285","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.2021.39.6_suppl.274","article-title":"Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC)","volume":"39","author":"Thouvenin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0290","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188823_bb0295","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188823_bb0300","article-title":"Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents","volume":"10","author":"Cao","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbcan.2022.188823_bb0305","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-18-0269","article-title":"Therapeutic targeting of TFE3\/IRS-1\/PI3K\/mTOR Axis in translocation renal cell carcinoma","volume":"24","author":"Damayanti","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22001482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22001482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:39:34Z","timestamp":1759639174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X22001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0304419X22001482"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188823","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188823"}}